what are gip and glp 1 receptors The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GIP Receptor: Activation and Blockade

Because it is not an approved drug, the BPC-157 sold online is supplied as a research compound

This is different because the entire case for BPC-157, as far as I can tell, boils down to I know someone who took it and was cured of something

Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule: Weeks 14: Inject 20 units (0.2 mL) one time per week Weeks 58: Inject 40 units (0.4 mL) one time per week Weeks 912: Inject 70 units (0.7 mL) one time per week Weeks 1316: Inject 90 units (0.9 mL) one time per week Weeks 1720: Inject 120 units (1.2 mL) one time per week Week 21+: Inject 140 units (1.4 mL) one time per week Dosing may deviate from this pattern to accommodate patient-specific needs

Josie got me started on compounded tirzepatide within a week

Contains 20mL of GlutaStat NS for IntraNasal Application

Suudhof, T